Gerhard Frey

Gerhard Frey

Company: BioAtla

Job title: Vice President, Technology Development


NextGen CAB-ADCs: Maximizing Safety & the Therapeutic Index 1:30 pm

Overviewing the CAB platform to minimize antigen related toxicity by pH-selective binding in the tumor microenvironment Optimizing linker selection for improved serum stability and tumor-targeted payload release Discussing approaches to maximize the therapeutic index of ADCsRead more

day: Track B - Pre-Conf- PM

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.